Adlai Nortye Ltd.
Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E recept… Read more
Market Cap & Net Worth: Adlai Nortye Ltd. (N2U0)
Adlai Nortye Ltd. (F:N2U0) has a market capitalization of $197.19 Million (€192.11 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #21914 globally and #2383 in its home market, demonstrating a -12.14% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Adlai Nortye Ltd.'s stock price €6.15 by its total outstanding shares 31236934 (31.24 Million).
Adlai Nortye Ltd. Market Cap History: 2026 to 2026
Adlai Nortye Ltd.'s market capitalization history from 2026 to 2026. Data shows growth from $197.19 Million to $197.19 Million (0.00% CAGR).
Adlai Nortye Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Adlai Nortye Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of N2U0 by Market Capitalization
Companies near Adlai Nortye Ltd. in the global market cap rankings as of March 19, 2026.
Key companies related to Adlai Nortye Ltd. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Adlai Nortye Ltd. Historical Marketcap From 2026 to 2026
Between 2026 and today, Adlai Nortye Ltd.'s market cap moved from $197.19 Million to $ 197.19 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €197.19 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Adlai Nortye Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $197.19 Million USD |
| MoneyControl | $197.19 Million USD |
| MarketWatch | $197.19 Million USD |
| marketcap.company | $197.19 Million USD |
| Reuters | $197.19 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.